Friday, January 27, 2017 10:32:02 AM
"On March 24,2016, Manzo issued a second press release, also drafted by Barton, restating the same misleading information contained in the February 16 press release.
At the same time that Manzo Pharmaceuticals issued the above misleading press releases, Barton, Goode and Peachtree converted their Manzo Pharmaceuticals debt into unregistered Manzo Pharmaceuticals stock and sold them to the public. All told, between June2014 and March 2016, Barton and Goode generated over $493,000 by selling 981 million shares of Manzo Pharmaceuticals stock"
https://www.sec.gov/litigation/complaints/2017/comp-pr2017-33.pdf
"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."
Upton Sinclair
"Nobody ever went broke underestimating the intelligence of the American public."
H. L. Mencken
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM